More specifically, in this case, our model has enabled us to identify a very promising CPT1/2 inhibitor for targeting ovarian cancer MRD as well as the key genes that we could target simultaneously to avoid the development of resistance. This evidence concerns the gene CPT2 and ovarian carcinoma.